Relief Therapeutics Holding SA (RLFB)

Switzerland
Currency in CHF
3.9000
-0.1000(-2.50%)
Closed
RLFB Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
3.78003.9000
52 wk Range
1.05507.6000
Key Statistics
Edit
Bid/Ask
3.78 / 3.98
Prev. Close
4
Open
3.8
Day's Range
3.78-3.9
52 wk Range
1.055-7.6
Volume
20.38K
Average Volume (3m)
100.84K
1-Year Change
131.21%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RLFB Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year
Show more

Relief Therapeutics Holding SA Company Profile

Relief Therapeutics Holding SA, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of rare metabolic, dermatological, and pulmonary diseases in Switzerland, Europe, North America, and internationally. The company offers SETOFILM/ONDISSOLVE for radiotherapy induced nausea and vomiting, and chemotherapy induced nausea and vomiting, as well as postoperative induced nausea and vomiting; OLPRUVA, a sodium phenylbutyrate for the treatment of urea cycle disorders, and maple syrup urine disease; and PKU GOLIKE for for the dietary management of phenylketonuria. It also develops TYR GOLIKE, that has completed Phase III clinical trial to treat Tyrosinemia; and RLF-100, a synthetic form of vasoactive intestinal peptide (VIP), that is in Phase II clinical trial for the treatment of acute respiratory distress syndrome (ARDS) associated with COVID-19 related ARDS and in preclinical trial to treat pulmonary sarcoidosis, checkpoint inhibitor-induced pneumonitis, and chronic berylliosis. In addition, the company also develops HCU GOLIKE, which is in Phase I clinical trial for the treatment of Homocystinuria; and RLF-TD011, a hypochlorous acid topical sprayable solution, that is in Phase I clinical trial to treat wound colonization, reduce local inflammation, alleviate symptoms, and hasten wound healing in epidermolysis bullosa. Further, it is developing RLF-OD32, which is in Phase I clinical trial for the treatment of patients with phenylketonuria; and. Relief Therapeutics Holding SA was founded in 2013 and is based in Geneva, Switzerland.

Compare RLFB to Peers and Sector

Metrics to compare
RLFB
Peers
Sector
Relationship
P/E Ratio
−1.0x−4.2x−0.6x
PEG Ratio
−0.020.000.00
Price/Book
1.0x1.6x2.6x
Price / LTM Sales
5.6x8.1x3.1x
Upside (Analyst Target)
-97.0%55.4%
Fair Value Upside
Unlock9.4%10.2%Unlock

Earnings

Latest Release
Apr 14, 2023
EPS / Forecast
-0.01 / --
Revenue / Forecast
1.54M / --
EPS Revisions
Last 90 days

People Also Watch

132.00
SRENH
+0.69%
155.80
UHR
-0.13%
4.670
QBTS
+21.93%
57.94
BAER
-0.55%
90.11
NOVN
-0.75%

FAQ

What Is the Relief Therapeutics (RLFB) Stock Price Today?

The Relief Therapeutics stock price today is 3.90

What Stock Exchange Does Relief Therapeutics Trade On?

Relief Therapeutics is listed and trades on the Switzerland stock exchange.

What Is the Stock Symbol for Relief Therapeutics?

The stock symbol for Relief Therapeutics is "RLFB."

What Is the Relief Therapeutics Market Cap?

As of today, Relief Therapeutics market cap is 48.91M.

What is Relief Therapeutics Earnings Per Share?

The Relief Therapeutics EPS is -3.70.

From a Technical Analysis Perspective, Is RLFB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.